Articles tagged with Fibrosis
Researchers developed a new 3D tissue model to understand and treat fibrosis, a disease that causes scarring in organs like lungs and kidneys. The model replicates the complexities of real disease and preserves natural cell diversity.
A new study found that moderate caloric restriction can preserve youthful ovarian follicles and reduce age-related tissue stiffness in rhesus macaques. This suggests that lifestyle-based strategies may help delay the decline in reproductive function associated with aging.
The Phase IIa trial of Rentosertib showed encouraging clinical data, with patients receiving the treatment experiencing significant improvements in lung function compared to placebo. The study also validated the biological mechanism of TNIK inhibition using exploratory biomarkers analyses.
Clinical trials for MASH cirrhosis have shown promising results, particularly with FGF21 analogues like efruxifermin and pegozafermin. The review emphasizes the need for effective interventions targeting advanced disease stages and highlights the importance of surrogate endpoints in accelerating approvals.
The international conference will focus on translating phage research into clinical reality, exploring key sessions and major speakers. Companies from various sectors are attending the event, highlighting the growing interest in phage therapy.
FibroFind's patented Precision Cut Tissue Slice (PCTS) platform preserves the architecture and function of both healthy and diseased human tissue, providing unparalleled translational accuracy. The acquisition is expected to scale FibroFind's reach across therapeutic areas and deepen its impact in pre-clinical drug development.
This study reveals periostin as a superior serum biomarker for diagnosing idiopathic pulmonary fibrosis, with high sensitivity and specificity compared to traditional markers. Periostin levels also correlate with disease severity and predict acute exacerbations in IPF patients.
Insilico Medicine will present detailed Phase IIa data on rentosertib, a novel TNIK inhibitor developed using generative AI, for the treatment of idiopathic pulmonary fibrosis (IPF). The company has previously demonstrated encouraging results from its Phase IIa study, showing favorable safety and tolerability across all dose levels.
This study elucidates the role of HO-1 in regulating NAFLD-related liver fibrosis through the SIRT1/TGF-β/Smad3 pathway. HO-1 overexpression reduced hepatic fibrosis by modulating the SIRT1/TGF-β/Smad3 signaling pathway.
Researchers developed a novel rat model that closely replicates human COPD-associated cor pulmonale, exhibiting chronic lung inflammation, pulmonary hypertension, and right ventricular hypertrophy. The model provides insights into the underlying mechanisms of disease progression and potential therapeutic targets.
Researchers at Tulane University identified a potential new way to treat idiopathic pulmonary fibrosis (IPF) using an FDA-approved cancer drug. The treatment works by blocking the CTLA4 protein, which blocks overactive T cells, allowing the immune system to clear out damaged cells that cause lung scarring.
A Phase 3 clinical study found that adding hydronidone to entecavir resulted in significant reversal of liver fibrosis. The trial aimed to identify the antifibrotic effect and safety of hydronidone for CHB patients with significant liver fibrosis.
Researchers have identified a potential precision medicine approach to prevent chronic kidney disease progression by targeting type 5 collagen, a minor component of scar tissue. A repurposed anti-cancer drug, Cilengitide, has been shown to slow kidney scarring and disease progression in high-risk individuals.
Scientists discovered a protein called HARS WHEP that calms inflammation in lung diseases by regulating white blood cells. The treatment efzofitimod showed promising results in reducing inflammation and fibrosis, providing new hope for patients suffering from sarcoidosis.
Researchers found that inhibiting S1pr3 reduces pulmonary fibrosis by reducing M2 macrophage polarization. S1pr3 inhibitors were also effective in ameliorating fibrosis in mice, suggesting a potential therapeutic strategy for humans.
Researchers have discovered a potential new treatment for pulmonary fibrosis by targeting the Piezo2 receptor, which plays a critical role in stiffness-mediated profibrotic fibroblast phenotypes. Inhibiting Piezo2 expression or function may slow disease progression and offer new therapeutic options.
Researchers at WashU have developed a method to manipulate the mechanical side of fibrosis, a complex condition that can lead to scarring and breathing difficulties. By controlling the direction of tension forces, they aim to prevent or treat fibrosis and develop personalized treatment plans for patients.
Direct-acting antivirals have reduced HCV-related morbidity and mortality, but hepatocellular carcinoma (HCC) risk persists in certain populations. Risk factors include pre-treatment cirrhosis, metabolic disorders, and advanced fibrosis, highlighting the need for tailored surveillance strategies.
A recent cohort study published in JAMA Internal Medicine found that statin use was associated with a reduced risk of hepatocellular carcinoma and hepatic decompensation in patients with chronic liver disease. This suggests that statins may play a role in preventing the progression of liver disease and reducing the risk of liver cancer.
Researchers at the University of Oklahoma are using a new $2 million grant to study the mechanisms of polycystic kidney disease (PKD), a family of genetic disorders causing clusters of cysts on the kidney. By identifying genes and proteins responsible for PKD, they aim to develop novel therapies.
Rentosertib, a breakthrough drug candidate for idiopathic pulmonary fibrosis (IPF), has been granted an official generic name by the USAN Council. The drug's development was accelerated using generative AI, identifying TNIK as a promising target and designing small-molecule compounds in just 18 months.
SLC transporters contribute to the development of hepatic steatosis by regulating lipid metabolism, particularly with SLC2A2, GLUT4, and GLUT5. These proteins influence processes like de novo lipogenesis and insulin resistance in hepatocytes.
The collaboration aims to close gaps in early recognition and management of IPF by equipping healthcare providers, public health professionals, and patients with necessary resources. The organizations will employ designated activities to build a knowledge base, develop survey tools, and create educational and awareness assets.
This disorder has diverse etiologies, variable presentations, and different therapeutic responses. The proposed diagnostic algorithm can differentiate pediatric MF subtypes to improve patient outcomes.
A collaborative study reveals two distinct types of scarring, referred to as “hot” and “cold,” which require entirely different treatments for diseased hearts. The researchers found that hot fibrosis is driven by an immune response, while cold fibrosis is a self-maintaining process.
Scientists have pinpointed two proteins in immune cells that, when blocked, can significantly reduce lung tissue scarring and restore regeneration. Blocking YAP and TAZ can curb scar formation by dampening inflammation, maintaining a healthy immune cell ratio, and disrupting their communication with nearby cells.
Researchers at TUM found that cystic fibrosis causes changes in the immune system as early as birth, leading to frequent inflammation and infections. These changes are not affected by CFTR modulator therapies.
A USF study found that patients with pulmonary fibrosis who contracted severe COVID-19 experienced lung improvement. Researchers are exploring factors associated with this finding to develop new treatments, including applying knowledge gained from COVID-19 patients to idiopathic pulmonary fibrosis patients. The study suggests a possibl...
A new approach to cancer therapy is being developed by inhibiting mechanotransduction, a process that regulates processes such as tumour progression and wound healing. The INTROPY project aims to validate the potential of six molecules in blocking this process, offering a new strategy for cancer treatment.
Researchers discovered that removing arginase-II gene can slow down muscle aging in mice, leading to improved muscle health and reduced inflammation. This finding suggests targeting the Arg-II gene could help maintain muscle strength and mobility in older adults.
Researchers reveal senescence's impact on liver health, from repair and regeneration to chronic disease progression. Emerging therapies, such as senolytic treatments, aim to selectively eliminate senescent cells while preserving healthy tissue.
Researchers found that previously thought 'pro-fibrotic' macrophages are not solely responsible for fibrosis and instead may contribute to healthy repair. The study aims to understand the triggers behind these differences in expression, with the goal of harnessing macrophages for lung repair.
Researchers have discovered that AHCC suppresses liver fibrosis by inhibiting the activation of hepatic stellate cells through two channels. Early administration of AHCC may hold the key to preventing the onset of cirrhosis, a potentially fatal condition.
Researchers have discovered that dextromethorphan, an FDA-approved ingredient found in many cough syrups, has potential to treat fibrotic lung disease. The study, published in Science Translational Medicine, showed how dextromethorphan can impede collagen formation, reducing lung scarring and stiffness.
Researchers discovered a novel combination of plasma-based biomarkers that can predict liver fibrosis in Latino adolescents with obesity. The study found that dihydroxyacetone phosphate (DHAP) and alanine transaminase (ALT) were significantly associated with fibrosis, suggesting a potential low-cost, noninvasive screening tool.
Longidaza significantly reduced exertional desaturation and dyspnea, as well as improved distance walked during the six-minute walk test. The drug's effects on exercise tolerance were sustained for over 100 days after treatment.
A new study published in Lancet Gastroenterology and Hepatology found that a combined screening approach can detect liver damage in people with type 2 diabetes. The method involves elastography, an ultrasound-based technique, which was found to be willing to be adopted by most patients. Early detection of liver fibrosis is crucial, as ...
A new study finds that a blood test using phosphatidylethanol (PEth) can detect liver disease caused by excessive drinking, offering a more reliable alternative to self-reported measures. The test has shown strong correlation with Fibrosis 4, an indicator of liver risk, and could be included in routine blood tests.
GLP-1RAs improve liver histology, reduce liver fat, and enhance metabolic parameters in MASLD patients. However, challenges remain in assessing long-term liver benefits and clarifying the effects on liver fibrosis.
Researchers identified plasma extracellular vesicle-derived microRNAs as potential biomarkers for AATD liver disease. They found 39 differentially expressed miRNAs, which were validated in an independent cohort for predicting AATD liver disease.
Researchers have identified a simpler and more accessible alternative to diagnosing kidney fibrosis in transplant patients: measuring vitronectin levels in urine. The study found that vitronectin levels were significantly higher in patients with fibrosis, and combining this measurement with traditional urine tests improved accuracy.
The Phase IIa trial of ISM001-055 showed dose-dependent improvement in forced vital capacity (FVC) and percent predicted FVC, suggesting potential to slow or reverse disease progression. The treatment also demonstrated a favorable pharmacokinetics profile with minimal adverse events.
Experimental mouse models are crucial for studying liver fibrosis regression, with various models exhibiting reversible fibrosis after removal of causative agents or therapeutic interventions. However, challenges persist in replicating human disease progression and regression, highlighting the need for further refinement of these models.
A cohort study reveals that AATD patients with COPD have a unique liver transcriptomic profile, with upregulated pathways related to fibrosis and inflammation. Histopathological analysis confirms higher levels of fibrosis and hepatocellular damage in these individuals.
A U.S.-based single-center retrospective cohort study found that advanced liver fibrosis is a primary risk factor for incident liver decompensation and liver-related events in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease. The study, published in the Journal of Clinical and Translational Hepatolog...
Gladstone researchers have identified a complex molecular connection between immune cells and fibroblasts that contributes to fibrosis in the heart, which may lead to new treatments for heart disease and other fibrotic conditions.
Researchers identified CYP1B1 as a biomarker for HSC activation and liver fibrosis in patients and mice. Inhibition of CYP1B1 led to the accumulation of trehalose, which has anti-fibrotic activity, protecting mice from liver fibrosis.
Researchers confirm that fibrosis in HER2-negative breast tumors is associated with an adverse prognosis and better treatment outcomes with nintedanib. A new test, MeCo Score, analyzes gene activity related to fibrosis and indicates the effectiveness of supplementing chemotherapy with antifibrotic therapy.
Researchers at the University of Barcelona have identified a potential new strategy to slow the development of liver fibrosis. Activating the PPARβ/δ-AMPK pathway has been found to prevent collagen accumulation and reduce inflammation in the liver, according to a study published in Biomedicine & Pharmacotherapy.
Researchers discovered a novel treatment that extends ovarian function in older mice by improving maintenance of the ovaries and preventing key age-related changes. The treatment also fixes hormone production and overall health, alleviating symptoms such as bone loss, cardiovascular disease, and cognitive decline.
Researchers identified protein kinase N as a key regulator of heart fibrosis, which threatens heart function. Deleting this enzyme reduced cardiac dysfunction, suggesting anti-PKN treatments may protect against heart failure.
A new study found that cystic fibrosis patients with more severe disease characteristics exhibit shorter leukocyte telomere length and greater LTL attrition. This association may accelerate aging and increase susceptibility to age-related diseases, emphasizing the importance of early CF diagnosis and timely therapeutic intervention.
Researchers discovered faulty immune processes responsible for lingering lung issues after COVID-19, which can be disrupted by existing drugs. The study also identified molecules responsible for the issue and potential therapeutic options for patients with ongoing lung damage.
A literature review examines key cell-cell interactions driving pulmonary fibrosis, revealing complex interplay between diverse lung cell types and intricate processes. The study highlights potential ligands involved in PF, including tumor necrosis factor, interleukin 1β, and ADAM17, and suggests targeting CCIs for novel therapies.
Researchers have identified key cellular interactions and microenvironments that contribute to the development of chronic kidney disease (CKD) after acute kidney injury (AKI) in mice. The study, published in Nature Communications, provides new insights into how damaged cells interact within disease-promoting microenvironments.
Researchers at Tokyo Medical and Dental University discovered the role of A20 in suppressing chronic hepatitis by inhibiting the DCLK1-JNK pathway-dependent chemokines. In mice lacking A20 expression, hepatic stellate cells displayed spontaneous inflammation and increased chemokine levels.
Researchers discovered a parasite protein that enhances wound healing in mice by stimulating immune cells to promote tissue regeneration and inhibit scarring. The protein, TGM, accelerates wound closure and improves skin regeneration.
Researchers at Sanford Burnham Prebys discovered that specific macrophage subpopulations, including TREM2+, are critical for resolving MASH and liver fibrosis. These cells help reduce inflammation, slow disease progression, and promote healing.
Researchers at the University of Virginia School of Engineering and Applied Science have designed a drug-carrying molecule that can slip past the lung's natural defenses. The nanocarrier, called PEG-BB, is shaped like a bottlebrush and mimics the properties of mucus, allowing it to move quickly through the airway.
A new study by Korea University College of Medicine shows that direct-acting antivirals significantly reduce liver-related clinical outcomes and lower the risk of disease progression to cancer or cirrhosis, increasing life expectancy for patients with Hepatitis C. The treatment approach has a high effectiveness rate of 90%.